S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:FLDM

Fluidigm Stock Forecast, Price & News

$4.11
+0.10 (+2.49 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.71
Now: $4.11
$4.12
50-Day Range
$4.01
MA: $5.98
$7.09
52-Week Range
$1.17
Now: $4.11
$12.45
Volume2.95 million shs
Average Volume3.49 million shs
Market Capitalization$306.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments, consumables, and services to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. Fluidigm Corporation sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Fluidigm logo

Headlines

Recap: Fluidigm Q4 Earnings - Yahoo Finance
February 12, 2021 |  finance.yahoo.com
Why Fluidigm Stock Is Sinking Today
February 11, 2021 |  finance.yahoo.com
Recap: Fluidigm Q4 Earnings - Benzinga
February 10, 2021 |  benzinga.com
Recap: Fluidigm Q4 Earnings
February 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
CUSIP34385P10
Phone650-266-6000
Employees566
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.24 million
Book Value$2.21 per share

Profitability

Net Income$-64,790,000.00

Miscellaneous

Market Cap$306.39 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

186th out of 1,968 stocks

Analytical Instruments Industry

6th out of 29 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$4.11
+0.10 (+2.49 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

Is Fluidigm a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fluidigm stock.
View analyst ratings for Fluidigm
or view top-rated stocks.

What stocks does MarketBeat like better than Fluidigm?

Wall Street analysts have given Fluidigm a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fluidigm wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Fluidigm
.

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) released its quarterly earnings results on Tuesday, February, 9th. The medical research company reported ($0.24) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.17. Fluidigm had a negative trailing twelve-month return on equity of 19.25% and a negative net margin of 37.85%.
View Fluidigm's earnings history
.

How has Fluidigm's stock been impacted by Coronavirus?

Fluidigm's stock was trading at $2.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FLDM shares have increased by 56.3% and is now trading at $4.11.
View which stocks have been most impacted by COVID-19
.

What guidance has Fluidigm issued on next quarter's earnings?

Fluidigm updated its FY 2021 After-Hours earnings guidance on Wednesday, February, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $144-155 million, compared to the consensus revenue estimate of $198.25 million.

What price target have analysts set for FLDM?

3 equities research analysts have issued 1-year price targets for Fluidigm's shares. Their forecasts range from $8.00 to $16.00. On average, they anticipate Fluidigm's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 192.0% from the stock's current price.
View analysts' price targets for Fluidigm
or view top-rated stocks among Wall Street analysts.

Who are Fluidigm's key executives?

Fluidigm's management team includes the following people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 48, Pay $688.72k)
  • Mr. Vikram Jog, Chief Financial Officer (Age 65, Pay $408.53k)
  • Mr. Bradley Allen Kreger, Sr. VP of Global Operations (Age 46, Pay $369.39k)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $350.47k)
  • Mr. Colin McCracken, Chief Commercial Officer (Age 48, Pay $456.65k)
  • Dr. Stephen R. Quake, Co-Founder & Chairman of Advisory Board
  • Mr. Andrew Quong, Chief Science Officer
  • Ms. Agnes Lee, VP of Investor Relations
  • Mark Spearman, Sr. Director of Corp. Communications
  • Ms. Angela Peters, Chief HR Officer

What is Chris Linthwaite's approval rating as Fluidigm's CEO?

30 employees have rated Fluidigm CEO Chris Linthwaite on Glassdoor.com. Chris Linthwaite has an approval rating of 78% among Fluidigm's employees.

Who are some of Fluidigm's key competitors?

What other stocks do shareholders of Fluidigm own?

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.53%), Primecap Management Co. CA (7.33%), Orbimed Advisors LLC (5.25%), Asymmetry Capital Management L.P. (2.08%), Paradigm Capital Management Inc. NY (2.06%) and Needham Investment Management LLC (1.69%). Company insiders that own Fluidigm stock include Levin Easterly Partners Llc, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite.
View institutional ownership trends for Fluidigm
.

Which major investors are selling Fluidigm stock?

FLDM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Assenagon Asset Management S.A., Primecap Management Co. CA, ExodusPoint Capital Management LP, Barclays PLC, GSA Capital Partners LLP, New York State Common Retirement Fund, and Engineers Gate Manager LP.
View insider buying and selling activity for Fluidigm
or view top insider-selling stocks.

Which major investors are buying Fluidigm stock?

FLDM stock was purchased by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Paradigm Capital Management Inc. NY, Needham Investment Management LLC, Orbimed Advisors LLC, Norges Bank, Alyeska Investment Group L.P., Alyeska Investment Group L.P., and BlackRock Inc.. Company insiders that have bought Fluidigm stock in the last two years include Nicolas Barthelemy, Samuel D Colella, and Stephen Christopher Linthwaite.
View insider buying and selling activity for Fluidigm
or or view top insider-buying stocks.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $4.11.

How much money does Fluidigm make?

Fluidigm has a market capitalization of $306.39 million and generates $117.24 million in revenue each year. The medical research company earns $-64,790,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis.

How many employees does Fluidigm have?

Fluidigm employs 566 workers across the globe.

What is Fluidigm's official website?

The official website for Fluidigm is www.fluidigm.com.

Where are Fluidigm's headquarters?

Fluidigm is headquartered at 2 Tower Place Ste 2000, South San Francisco CA, 94080.

How can I contact Fluidigm?

Fluidigm's mailing address is 2 Tower Place Ste 2000, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.